Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective

Peritoneal carcinomatosis remains a devastating manifestation of advanced intra-abdominal malignancies. Management and therapy of this clinical entity, which balance efforts to extend survival and improve quality of life, have been challenging and have evolved significantly over the last century (Figure 1). Substantial strides have been made in the surgical arena to achieve safe clearance of macroscopic disease by means of cytoreductive surgery (CRS) and more recently, combined with hyperthermic intraperitoneal chemotherapy (HIPEC), for treatment of microscopic or minimal volume disease.

Continue reading on